Literature DB >> 25998049

Schwann Cells Metabolize Extracellular 2',3'-cAMP to 2'-AMP.

Jonathan D Verrier1, Patrick M Kochanek1, Edwin K Jackson2.   

Abstract

The 3',5'-cAMP-adenosine pathway (3',5'-cAMP5'-AMPadenosine) and the 2',3'-cAMP-adenosine pathway (2',3'-cAMP2'-AMP/3'-AMPadenosine) are active in the brain. Oligodendrocytes participate in the brain 2',3'-cAMP-adenosine pathway via their robust expression of 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase; converts 2',3'-cAMP to 2'-AMP). Because Schwann cells also express CNPase, it is conceivable that the 2',3'-cAMP-adenosine pathway exists in the peripheral nervous system. To test this and to compare the 2',3'-cAMP-adenosine pathway to the 3',5'-cAMP-adenosine pathway in Schwann cells, we examined the metabolism of 2',3'-cAMP, 2'-AMP, 3'-AMP, 3',5'-cAMP, and 5'-AMP in primary rat Schwann cells in culture. Addition of 2',3'-cAMP (3, 10, and 30 µM) to Schwann cells increased levels of 2'-AMP in the medium from 0.006 ± 0.002 to 21 ± 2, 70 ± 3, and 187 ± 10 nM/µg protein, respectively; in contrast, Schwann cells had little ability to convert 2',3'-cAMP to 3'-AMP or 3',5'-cAMP to either 3'-AMP or 5'-AMP. Although Schwann cells slightly converted 2',3'-cAMP and 2'-AMP to adenosine, they did so at very modest rates (e.g., 5- and 3-fold, respectively, more slowly compared with our previously reported studies in oligodendrocytes). Using transected myelinated rat sciatic nerves in culture medium, we observed a time-related increase in endogenous intracellular 2',3'-cAMP and extracellular 2'-AMP. These findings indicate that Schwann cells do not have a robust 3',5'-cAMP-adenosine pathway but do have a 2',3'-cAMP-adenosine pathway; however, because the pathway mostly involves 2'-AMP formation rather than 3'-AMP, and because the conversion of 2'-AMP to adenosine is slow, metabolism of 2',3'-cAMP mostly results in the accumulation of 2'-AMP. Accumulation of 2'-AMP in peripheral nerves postinjury could have pathophysiological consequences.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25998049      PMCID: PMC4518068          DOI: 10.1124/jpet.115.225219

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  47 in total

Review 1.  Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology.

Authors:  J C Shryock; L Belardinelli
Journal:  Am J Cardiol       Date:  1997-06-19       Impact factor: 2.778

Review 2.  Cardiovascular adenosine receptors: expression, actions and interactions.

Authors:  John P Headrick; Kevin J Ashton; Roselyn B Rose'meyer; Jason N Peart
Journal:  Pharmacol Ther       Date:  2013-06-10       Impact factor: 12.310

Review 3.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

4.  The brain in vivo expresses the 2',3'-cAMP-adenosine pathway.

Authors:  Jonathan D Verrier; Travis C Jackson; Rashmi Bansal; Patrick M Kochanek; Ava M Puccio; David O Okonkwo; Edwin K Jackson
Journal:  J Neurochem       Date:  2012-03-20       Impact factor: 5.372

5.  AMP is an adenosine A1 receptor agonist.

Authors:  Joseph E Rittiner; Ilia Korboukh; Emily A Hull-Ryde; Jian Jin; William P Janzen; Stephen V Frye; Mark J Zylka
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

6.  Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor.

Authors:  B Johansson; L Halldner; T V Dunwiddie; S A Masino; W Poelchen; L Giménez-Llort; R M Escorihuela; A Fernández-Teruel; Z Wiesenfeld-Hallin; X J Xu; A Hårdemark; C Betsholtz; E Herlenius; B B Fredholm
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

Review 7.  Local modulation of adrenergic neurotransmission in blood vessels.

Authors:  J T Shepherd; P M Vanhoutte
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

Review 8.  2',3'-cyclic nucleotide 3'-phosphodiesterase, an oligodendrocyte-Schwann cell and myelin-associated enzyme of the nervous system.

Authors:  T J Sprinkle
Journal:  Crit Rev Neurobiol       Date:  1989

9.  Energetics of catalysis by ribonucleases: fate of the 2',3'-cyclic phosphodiester intermediate.

Authors:  J E Thompson; F D Venegas; R T Raines
Journal:  Biochemistry       Date:  1994-06-14       Impact factor: 3.162

Review 10.  The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects.

Authors:  Beáta Sperlágh; E Sylvester Vizi
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

View more
  1 in total

Review 1.  Purines: forgotten mediators in traumatic brain injury.

Authors:  Edwin K Jackson; Detlev Boison; Michael A Schwarzschild; Patrick M Kochanek
Journal:  J Neurochem       Date:  2016-02-25       Impact factor: 5.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.